Archerfish Precision Diagnostics
Archerfish Precision Diagnostics is a Singapore-based CAP-accredited molecular diagnostics laboratory, formed in 2025 via merger of Angsana and Pathnova, offering NGS-based oncology, NPC screening, and allergy diagnostics, while distributing C2N and ClearNote products across Asia for healthcare providers, government systems, and pharma partners.
- Company typePrivate
- Founded2025
- HeadquartersSingapore, Singapore
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Archerfish Precision Diagnostics does
Archerfish Precision Diagnostics Pte Ltd is a Singapore-headquartered clinical molecular diagnostics laboratory formed in March 2025 through the merger of two CAP-accredited entities — Angsana Molecular & Diagnostics Laboratory and Pathnova Laboratories. The company operates from two Singapore sites (67 Ubi Avenue 1 and 1 Research Link on the NUS campus), employs 11–50 people, and positions itself as a regional platform serving both private and public healthcare sectors in Singapore and across Asia. Angsana brought commercialized molecular oncology capability (the first clinical NGS provider in Asia), while Pathnova contributed proprietary serology, AI-enhanced assays, and a nasopharyngeal carcinoma (NPC) early screening test focused on Asian-prevalent diseases.
The company's core technology stack combines Next-Generation Sequencing (NGS) for tumor mutation profiling, metagenomic NGS (mNGS) for infectious disease detection, AI-enhanced serology, serum proteomics via aptamer technology profiling thousands of proteins, and high-resolution LC-MS/MS. Service offerings include molecular oncology NGS, allergy and molecular allergology, NPC early screening, and contract research/consulting for pharma and biotech partners. Through distribution partnerships, the company also delivers third-party diagnostic products — notably the C2N Diagnostics PrecivityAD2 Alzheimer's blood test and ClearNote Health liquid biopsy assays — across Asia, with Singapore as the launch hub.
Revenue is generated via professional-services fees for laboratory testing (pricing is quote-based and not publicly disclosed), contract research and consulting for pharmaceutical clients, and distribution/licensing economics on partner-dispatched products. The business is backed by a consortium of Temasek-affiliated strategic investors (Temasek Life Sciences Laboratory, The Life Sciences Innovation Fund, Temasek Life Sciences Accelerator, and SEEDS Capital), and the company is targeting at least SGD $50 million over three years to fund technology development, commercialization, and regional expansion into seven or more additional Asian markets.
Archerfish Precision Diagnostics firmographics
Firmographics- Name
- Archerfish Precision Diagnostics
- Legal name
- Archerfish Precision Diagnostics Pte Ltd
- Website
- https://archerfishdx.com
- Company type
- Private
- Founded year
- 2025
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Archerfish Precision Diagnostics is a Singapore-based CAP-accredited molecular diagnostics laboratory, formed in 2025 via merger of Angsana and Pathnova, offering NGS-based oncology, NPC screening, and allergy diagnostics, while distributing C2N and ClearNote products across Asia for healthcare providers, government systems, and pharma partners.
- Ownership category
- akta.pro rank
Archerfish Precision Diagnostics industry classification
Industry- Product category
- Clinical Diagnostic Laboratory Services
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Testing Laboratories (8734), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)
- akta.pro secondary industries
- Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)
Keywords
Where Archerfish Precision Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Singapore
- HQ country
- Singapore
- HQ region
- Asia
Offices2 records
Markets served
Archerfish Precision Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure
Revenue model
- Clinical Diagnostic Laboratory Services: CAP-accredited laboratory testing services including molecular oncology, allergy diagnostics, and cancer screening tests offered to healthcare providers and patients in private and public healthcare sectors.
- Contract Research Services: Support for clinical research and trials tailored to specific needs of pharmaceutical and biotechnology partners, leveraging laboratory capabilities and expertise.
- Consulting Services and Partnership: Scientific expertise and collaborative partnerships offered to help partners achieve research and development goals in diagnostics.
- Diagnostic Product Distribution: Distribution of diagnostic products including ClearNote Health liquid biopsy tests and C2N Diagnostics PrecivityAD2 test across Asia through partnership agreements.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
Archerfish Precision Diagnostics product offering
Product offeringCore offering
Archerfish Precision Diagnostics operates two merged CAP-accredited clinical laboratories (Angsana Molecular & Diagnostics Laboratory and Pathnova Laboratories) providing molecular diagnostics services including NGS-based molecular oncology profiling, allergy and molecular allergology testing, and proprietary nasopharyngeal carcinoma (NPC) early screening. The company also offers contract research and consulting services to pharmaceutical and biotechnology partners. Through distribution partnerships, Archerfish extends its portfolio to include the C2N Diagnostics PrecivityAD2 blood test for Alzheimer's disease and ClearNote Health liquid biopsy tests across Asia.
Product overview
Archerfish Precision Diagnostics operates as a molecular diagnostics laboratory offering a portfolio of clinical diagnostic services. The core service offerings include Molecular Oncology (NGS-based cancer mutation profiling), Allergy and Molecular Allergology, and Nasopharyngeal Carcinoma (NPC) Screening—these services originated from the merger of Angsana Molecular & Diagnostics Laboratory (NGS pioneer in Asia) and Pathnova Laboratories (serology and AI specialist). Supporting services include Contract Research and Consulting Services for industry partners. Through strategic partnerships, Archerfish distributes additional diagnostic products including the C2N Diagnostics PrecivityAD2™ blood test for Alzheimer's disease diagnosis and ClearNote Health liquid biopsy tests. Both constituent labs (Angsana and Pathnova) are CAP-accredited. The company is pursuing expansion into infectious disease detection via metagenomic NGS and data-driven disease detection through serum proteomics and serological profiling.
Differentiator
Problem solved
Functional benefit
Products and services
- Molecular Oncology (Next-Generation Sequencing) Next-Generation Sequencing service that sequences numerous genes simultaneously to identify genetic mutations in tumors, enabling personalized cancer treatment selection. Offered to healthcare providers including hospitals and clinics.
- Allergy and Molecular Allergology
Quantifiable outcome
- Over 90% accuracy compared to cerebrospinal fluid analysis or amyloid PET analysis in JAMA-published clinical care study (PrecivityAD2 test)
- +2 more outcomes
Companies that use Archerfish Precision Diagnostics
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles4 records
Archerfish Precision Diagnostics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature6 records
Archerfish Precision Diagnostics partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- ClearNote HealthcoreStrategic partnership for distribution of ClearNote Health's liquid biopsy tests in Asia, beginning with Singapore as the regional launch hub. Archerfish will leverage its laboratory expertise and network to expand access to liquid biopsy testing across Asian markets.
- C2N DiagnosticscorePartnership to distribute C2N's PrecivityAD2 blood test for Alzheimer's disease diagnosis across Singapore and Asia. The test demonstrates over 90% accuracy compared to cerebrospinal fluid or amyloid PET analysis. Archerfish is one of six international partners in C2N's global expansion targeting regions with inadequate PET infrastructure and aging populations.
- Accuserv Diagnostic CenterminorInternational partner in C2N Diagnostics global expansion network for PrecivityAD2 test distribution.
- Codex GeneticsminorInternational partner in C2N Diagnostics global expansion network for PrecivityAD2 test distribution.
- Dr. Dangs LabminorInternational partner in C2N Diagnostics global expansion network for PrecivityAD2 test distribution.
- Medical LinkminorInternational partner in C2N Diagnostics global expansion network for PrecivityAD2 test distribution.
- Milenia LabsminorInternational partner in C2N Diagnostics global expansion network for PrecivityAD2 test distribution.
Scale indicators4 records
Recent moves1 record
Archerfish Precision Diagnostics competitors and assessment
Company assessmentBroad incumbents
- Guardant Health: US-listed liquid biopsy and NGS-based molecular diagnostics company with a broad oncology-focused menu. Comparable to Archerfish on NGS-based cancer testing technology and the ClearNote Health liquid biopsy distribution partnership that Archerfish represents across Asia.
- BGI Genomics: China-headquartered genomics and molecular diagnostics provider with broad NGS-based clinical testing services across Asia. Directly comparable as a large-scale regional molecular diagnostics incumbent targeting similar oncology and infectious disease applications.
- Sonic Healthcare: Global medical laboratory operator with extensive Asia-Pacific presence providing clinical diagnostic services to hospitals and physicians. Comparable as a broad diagnostics lab incumbent competing with Archerfish's CAP-accredited clinical laboratory services across the region.
- Natera: US molecular diagnostics company specializing in cell-free DNA and NGS-based testing across oncology and reproductive health. Comparable on NGS-based liquid biopsy technology that overlaps with Archerfish's ClearNote Health partnership distribution.
Direct peers
- NeoGenomics: US-based clinical laboratory specializing in oncology-focused molecular diagnostics and NGS profiling for hospitals and clinicians. Closely comparable business model to Archerfish's molecular oncology NGS service serving healthcare providers.
- Novogene: Asia-headquartered genomics services company providing NGS-based clinical and research testing across oncology, reproductive health, and infectious disease. Comparable to Archerfish on multi-omic NGS service menu, regional Asia presence, and clinical/research split.
Emerging players
- C2N Diagnostics: US developer of the PrecivityAD2 blood-based Alzheimer's diagnostic test that Archerfish distributes across Asia under partnership. Comparable technology (LC-MS/MS-based blood biomarker testing) and represents the innovator whose product Archerfish commercializes regionally.
- ClearNote Health: US-based liquid biopsy company whose tests Archerfish distributes across Asia via partnership. Comparable on liquid biopsy and NGS-based cancer detection technology underlying the products Archerfish sells to regional healthcare providers.
Others
- MGI Tech: Asia-based provider of NGS sequencing platforms and laboratory automation used by clinical diagnostics labs. Comparable as a regional technology infrastructure provider in the NGS ecosystem in which Archerfish operates its molecular oncology and mNGS services.
Regional players
- Innoquest Diagnostics: Singapore-based medical diagnostics laboratory serving hospitals and clinicians with clinical testing services. Most direct domestic peer competing with Archerfish in the Singapore private and public healthcare sector for molecular and specialty testing volume.
Market position
Strengths5 records
Weaknesses5 records
Key risks6 records
Key highlights6 records
Customer concentration
Archerfish Precision Diagnostics social profiles
Digital presenceArcherfish Precision Diagnostics compliance and trust
Trust signalCompliance1 record
Archerfish Precision Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Archerfish Precision Diagnostics leadership team
Management profileNumber of profiles
Profiles7 records
Archerfish Precision Diagnostics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Archerfish Precision Diagnostics M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Archerfish Precision Diagnostics
What does Archerfish Precision Diagnostics do?
Archerfish Precision Diagnostics operates two merged CAP-accredited clinical laboratories (Angsana Molecular & Diagnostics Laboratory and Pathnova Laboratories) providing molecular diagnostics services including NGS-based molecular oncology profiling, allergy and molecular allergology testing, and proprietary nasopharyngeal carcinoma (NPC) early screening. The company also offers contract research and consulting services to pharmaceutical and biotechnology partners. Through distribution partnerships, Archerfish extends its portfolio to include the C2N Diagnostics PrecivityAD2 blood test for Alzheimer's disease and ClearNote Health liquid biopsy tests across Asia.
Is Archerfish Precision Diagnostics a public or private company?
Archerfish Precision Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Archerfish Precision Diagnostics founded?
Archerfish Precision Diagnostics was founded in 2025. It employs 11 to 50 people.
Where is Archerfish Precision Diagnostics based?
Archerfish Precision Diagnostics is headquartered in Singapore, Singapore, in the Asia region.
How does Archerfish Precision Diagnostics make money?
Four revenue lines are on record. Clinical Diagnostic Laboratory Services are the primary driver. The others are contract Research Services, consulting Services and Partnership and diagnostic Product Distribution.
Who are Archerfish Precision Diagnostics's main competitors?
Broad incumbents on record are Guardant Health, BGI Genomics, Sonic Healthcare and Natera. Direct peers are NeoGenomics and Novogene. Emerging players are C2N Diagnostics and ClearNote Health. MGI Tech is listed as an others. Innoquest Diagnostics is listed as a regional player.
Does Archerfish Precision Diagnostics have an API?
No public API is recorded for Archerfish Precision Diagnostics.
What industry is Archerfish Precision Diagnostics in?
Archerfish Precision Diagnostics's product category is Clinical Diagnostic Laboratory Services. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD), with a secondary code of HLAGADAF, Molecular & Genetic Testing (PCR/NGS/qPCR). Its NAICS code is 621511 and its SIC code is 2835.